CoChat
Sign Up
Cited by 1,149Diabetes Management and ResearchDiabetes and associated disordersDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 34 of the 36 references it cites were found in a registry or an index.

Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study

Gregory, Gabriel A, Robinson, Thomas I G, Linklater, Sarah E, Wang, Fei, Colagiuri, Stephen, de Beaufort, Carine, Donaghue, Kim C, Harding, Jessica L, Wander, Pandora L, Zhang, Xinge, Li, Xia, Karuranga, Suvi, Chen, Hongzhi, Sun, Hong, Xie, Yuting, Oram, Richard, Magliano, Dianna J, Zhou, Zhiguang, Jenkins, Alicia J, Ma, Ronald CW, Magliano, Dianna J, Maniam, Jayanthi, Orchard, Trevor J, Rai, Priyanka, Ogle, Graham D·2022·The Lancet Diabetes & Endocrinology
DOI 10.1016/s2213-8587(22)00218-2
Open this paper in CoChat — free account

Abstract

Background Accurate data on type 1 diabetes prevalence, incidence, associated mortality and life expectancy are crucial to inform public health policy, but these data are scarce. We therefore developed a model based on available data to estimate these values for 201 countries for the year 2021 and estimate the projected prevalent cases in 2040.Methods We fitted a discrete-time illness-death model (Markov model) to data on type 1 diabetes incidence and type 1 diabetes-associated mortality to produce type 1 diabetes prevalence, incidence, associated mortality and life expectancy in all countries. Type 1 diabetes incidence and mortality data were available from 97 and 37 countries respectively. Diagnosis rates were estimated using data from an expert survey. Mortality was modelled using random-forest regression of published type 1 diabetes mortality data, and life expectancy was calculated accordingly using life tables. Estimates were validated against observed prevalence data for 15 countries. We also estimated missing prevalence (the number of additional people who would be alive with type 1 diabetes if their mortality matched general population rates).Findings In 2021, there were about 8·4 (95% uncertainty interval 8·1-8·8) million individuals worldwide with type 1 diabetes: of these 1·5 million (18%) were younger than 20 years, 5·4 million (64%) were aged 20-59 years, and 1·6 million (19%) were aged 60 years or older. In that year there were 0·5 million new cases diagnosed (median age of onset 39 years), about 35 000 non-diagnosed individuals died within 12 months of symptomatic onset. One fifth (1·8 million) of individuals with type 1 diabetes were in low-income and lower-middle-income countries. Remaining life expectancy of a 10-year-old diagnosed with type 1 diabetes in 2021 ranged from a mean of 13 years in low-income countries to 65 years in high-income countries. Missing prevalent cases in 2021 were estimated at 3·7 million. In 2040, we predict an increase in prevalent cases to 13·5-17·4 million (60-107% higher than in 2021) with the largest relative increase versus 2021 in low-income and lower-middle-income countries.Interpretation The burden of type 1 diabetes in 2021 is vast and is expected to increase rapidly, especially in resource-limited countries. Most incident and prevalent cases are adults. The substantial missing prevalence highlights the premature mortality of type 1 diabetes and an opportunity to save and extend lives of people with type 1 diabetes. Our new model, which will be made publicly available as the Type 1 Diabetes Index model, will be an important tool to support health delivery, advocacy, and funding decisions for type 1 diabetes.Funding JDRF International.

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(22)00218-2

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 36 references

Research works printed but not linked: 3

  1. International Diabetes Federation. IDF Diabetes Atlas, 10th edition. Brussels, Belgium, 2021.
  2. 1890, Diabetes in children, Lancet, 135
  3. International Diabetes Federation. IDF Diabetes Atlas, 7th edition. Brussels, Belgium, 2015.

Cited by

Sorted by citations

Items 901–999 of 999

Related

See all

Metadata

Authors
Gregory, G. A., Robinson, T. I. G., Linklater, S. E., Wang, F., Colagiuri, S., de Beaufort, C., Donaghue, K. C., Harding, J. L., Wander, P. L., Zhang, X., Li, X., Karuranga, S., Chen, H., Sun, H., Xie, Y., Oram, R., Magliano, D. J., Zhou, Z., Jenkins, A. J., Ma, R. C., Magliano, D. J., Maniam, J., Orchard, T. J., Rai, P., & Ogle, G. D.
Affiliations
  • The University of Sydney (AU)
  • Juvenile Diabetes Research Foundation (AU)
  • Baker Heart and Diabetes Institute (AU)
  • University of Pittsburgh (US)
Corresponding author
Karuranga, Suvi
ORCID
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2022-10
Volume
10
Issue
10
Pages
741-760
ISSN
2213-8587 (ISSN-L)
DOI
10.1016/s2213-8587(22)00218-2
OpenAlex
W4296162804
Cited by
1,149
References
36
Citations by year
2026: 232 · 2025: 358 · 2024: 342 · 2023: 202 · 2022: 15
FWCI
170.51
Type
journal article
Language
en
Update notices
erratum (2022-11-01)
Open access
closed
Licence
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Abbott Diabetes Care
  • University of Sydney Sydney Medical School
  • Leona M. and Harry B. Helmsley Charitable Trust
  • Juvenile Diabetes Research Foundation United States of America
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 1 diabetes, diabetes prevalence, diabetes incidence, diabetes mortality, life expectancy, disease burden, global health burden, low-income countries, undiagnosed cases, illness-death model, Markov model, random forest regression, age of onset, underdiagnosis, public health policy, health equity
MeSH terms
Adult, Child, Diabetes Mellitus, Type 1, Humans, Life Expectancy, Global Health, Incidence, Prevalence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review